Preclinical and clinical evaluation of siddha classical drug ATHIVIDAYA RASAYANAM (oral administration) in the management of BACILLARY DYSENTERY in children

Preclinical and clinical evaluation of the effect on oral administration of ATHIVIDAYA RASAYANAM in the management of MOOLA KANAM (BACILLARY DYSENTERY) in children

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/10/046781

Enrollment

Registered

2022-10-26

Start date

Unknown

Completion date

Unknown

Last updated

2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A039- Shigellosis, unspecified

Interventions

Intervention1: ATHIVIDAYA RASAYANAM (Oral administration): Should be administrated orally twice a day after food for 21 days Dosage:(According to age of the patients) 3-5 years - 1 to 2 gm 5-7 years -

Eligibility

Inclusion criteria

Inclusion criteria: Dysentery Fever Abdominal pain Headache

Exclusion criteria

Exclusion criteria: Ulcerative colitis Celiac disease Malena Acute diarrhoeal disease

Design outcomes

Primary

Measure	Time frame
This study will help to understand the effects of ATHIVIDAYA RASAYANAM in the management of MOOLA KANAM(BACILLARY DYSENTERY) in children and the specific symptoms will expected to be curedTimepoint: 21 days	—

Secondary

Measure	Time frame
NilTimepoint: Nil	—

Countries

India

Contacts

Public ContactProf Dr D K Soundararajan

Government Siddha Medical College and Hospital Palayamkottai

dr.dks2012@gmail.com9442048801

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026